Information Provided By:
Fly News Breaks for September 24, 2018
HZNP
Sep 24, 2018 | 06:25 EDT
After hosting a call featuring an expert focused on thyroid eye disease, also known as Graves' orbitopathy, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Horizon Pharma with a $25 price target. The analyst says commentary from the expert heightened his confidence that Horizon's teprotumumab "will emerge as a paradigm-shifting option" in the broader thyroid eye disease treatment landscape. The expert views teprotumumab not only as a means of avoiding surgical intervention but also as a potential option in less severe patients who are not necessarily headed for surgery, Amsellem tells investors in a research note. He believes Horizon remains well positioned for long-term annual EBITDA growth "that is solidly in the double-digits."
News For HZNP From the Last 2 Days
There are no results for your query HZNP